FDA Approves Atezolizumab as a First-Line Treatment for Metastatic NSCLC Subgroup

Atezolizumab was approved as a first-line treatment for adults with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression, as determined by an FDA approved test, with no EGFR or ALK genomic tumor aberrations.

Source: CancerNetwork - May 18, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news